Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  saracatinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-19 of 19 for your search:
Start Over
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/09/105, Funder reference (academic), Funder reference (industry), 2009-017171-13, NCT01196741
AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: I173, CAN-NCIC-IND173, ZENECA-CAN-NCIC-IND173, CDR0000450844, IND173, NCT00265876
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02842, PHII-79, N01CM62209, N01CM62201, CDR0000559142, CCC-PHII-79, CHNMC-PHII-79, 7583, NCT00513071
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00192, 06-074, CDR0000559632, N01CM62206, MSKCC-06074, 7584, NCT00513435
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01831, NCCTG-N0621, CDR0000563952, N0621, U10CA025224, NCT00528645
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00191, MSKCC-07112, N01CM62204, N01CM62206, CDR0000574281, 07-112, 7567, NCT00559507
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8180C00034, NCT00558272
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00188, PHL-052, CDR0000585708, PMH-PHL-052, N01CM62203, 7552, NCT00607594
Saracatinib in Treating Patients With Recurrent, Stage IIIB or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy That Included Cisplatin or Carboplatin
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01053, PMH-PHLO-053, CDR0000587610, PHL-053, 7555, N01CM00032, N01CM62203, PHLO-053, NCT00638937
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8180C00015, AZD0530 Study 15, NCT00610714
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01054, PHL-054, CDR0000588034, PMH-PHL-054, N01CM62203, 7557, NCT00659360
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00193, N01CM62201, CDR0000594729, 16077A, UCCRC-16077A, 7597, NCT00669019
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00297, IUCRO-0214, IUMC-IUCRO-0214, 8236, NCT00718809
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00194, MAYO-MC0547, CDR0000610063, MC0547, 7602, P30CA015083, N01CM62205, NCT00735917
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Phase: Phase II
Type: Treatment
Status: Closed
Age: 15 to 74
Sponsor: Other
Protocol IDs: SARC012, D8180C00039, NCT00752206
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00014, EuDract #2006-003505-55, NCT00475956
Phase I Study in Patients With Solid Tumours
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8180C00023, AZD0530 study 23, NCT00496028
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8180C00021, NCT00704366
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: SLAM 7601, NCT02116712
Start Over